Diviti

Indonesia • Dexa Medica

Indication

Prevention of venous thromboembolic events (VTE) in:

  • Patients undergoing major orthopedic surgery of the lower limbs, such as hip fracture including extended prophylaxis, knee replacement surgery, hip replacement surgery.
  • Patients undergoing abdominal surgery who are at risk of thromboembolic complications.
  • Medical patients who are at risk for VTE and who are thromboembolic complications due to restricted mobility during acute illness.

Composition

Fondaparinux 2.5 mg

Package

2 prefilled syringes of 0.5 ml

Dosage Forms

Pre-filled Syringe

ATC Classification

B01A

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Consult Your Doctor
Safety of this item for use while operating heavy machinery has not been established. Please consult your doctor.
Pregnancy
Not Recommended
This item is not safe for use during pregnancy.
Lactation
Not Recommended
This item is not safe for use during lactation.

Dosage

0 to 17 Years Old

The safety and efficacy of fondaparinux sodium in patients under the age of 17 has not been established.

17 to 75 Years Old

Orthopedic and abdominal surgery:
The recommended dose of fondaparinux sodium is 2.5 mg once daily, administered postoperatively by subcutaneous injection. The timing of the first dose should be no earlier than 6 hours following surgical closure, and only after hemostasis has been established. Duration of treatment usually until the patient is ambulant, at least 5 to 9 days after surgery.

Medical patients at risk of thromboembolic complications:
The recommended dose of fondaparinux sodium is 2.5 mg once daily administered by subcutaneous injection. Treatment duration is about 6 to 14 days.

75 Years Old and Above

Fondaparinux sodium should be used with caution in elderly patients as renal function decreases with age.

Patients with Renal Impairment

Fondaparinux sodium should not be used in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage reduction is required for patients with mild or moderate renal impairment.

Patients with Hepatic Impairment

No dosing adjustment of fondaparinux sodium is necessary. In patients with severe hepatic impairment, fondaparinux sodium should be used with caution.

Patients with Body Weight Less Than 50 kg

Patients with body weight less than 50 kg are at increased risk of bleeding. For prophylaxis following surgery fondaparinux sodium should be used with caution in these patients.

Product Data